Document:

Exhibit 10.2

 

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

 

THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made effective as of the 24th day of March, 2015, by and between KELLY W. GEORGE (the “Executive”) and MACKINAC FINANCIAL CORPORATION, a Michigan corporation (the “Company”).

 

BACKGROUND

 

On August 10, 2012, the Company and the Executive entered into an Employment Agreement (the “Employment Agreement”).  The Company and the Executive now wish to amend the Employment Agreement as provided herein.

 

NOW, THEREFORE, in consideration of the foregoing and the terms and conditions set forth below, the parties agree as follows:

 

TERMS AND CONDITIONS

 

1.                                      AMENDMENT TO DEFINED TERM.  The term “Commencement Date” as used in the Employment Agreement is hereby amended to be March 24, 2015.

 

2.                                      AMENDMENT TO SECTION 2(B)(I).  The first sentence of Section 2(b)(i) of the Employment Agreement is hereby deleted in its entirety and amended to read as follows:

 

“During the Employment Period, the Executive shall receive an annual base salary at least equal  to Three Hundred One Thousand Three Hundred Fifty 14/100 ($301,350.14) (the “Annual Base Salary”), which shall be paid in accordance with the Company’s normal payroll practices for senior executive officers of the Company as in effect from time to time.”

 

3.                                      CONSTRUCTION.  Unless otherwise defined herein, capitalized terms shall have the meanings set forth in the Employment Agreement.  The terms of this Amendment amend and modify the Employment Agreement as if fully set forth in the Employment Agreement.  If there is any conflict between the terms, conditions and obligations of this Amendment and the Employment Agreement, this Amendment’s terms, conditions and obligations shall control.  All other provisions of the Employment Agreement not specifically modified by this Amendment are preserved.  This Amendment may be executed in counterparts (including via facsimile or .pdf), each of which shall be deemed an original, and all of which together shall constitute one and the same document.

 

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first written above.

 

	
THE EXECUTIVE:  
    	
THE COMPANY:  
    
	
 
    	
 
    
	
 
    	
 
    	
MACKINAC FINANCIAL   CORPORATION  
    
	
 
    	
 
    	
 
    
	
/s/ KELLY W.   GEORGE  
    	
 
    	
By: 
    	
/s/ PAUL D. TOBIAS  
    
	
KELLY W. GEORGE
    	
 
    	
Name: 
    	
Paul D. Tobias  
    
	
 
    	
 
    	
Title: 
    	
CEO and ChairmanExhibit 10.3

 

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

 

THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made effective as of the 24th day of March, 2015, by and between ERNIE R. KRUEGER (the “Executive”) and MACKINAC FINANCIAL CORPORATION, a Michigan corporation (the “Company”).

 

BACKGROUND

 

On August 10, 2012, the Company and the Executive entered into an Employment Agreement (the “Employment Agreement”).  The Company and the Executive now wish to amend the Employment Agreement as provided herein.

 

NOW, THEREFORE, in consideration of the foregoing and the terms and conditions set forth below, the parties agree as follows:

 

TERMS AND CONDITIONS

 

1.                                      AMENDMENT TO DEFINED TERM.  The term “Commencement Date” as used in the Employment Agreement is hereby amended to be March 24, 2015.

 

2.                                      AMENDMENT TO SECTION 2(B)(I).  The first sentence of Section 2(b)(i) of the Employment Agreement is hereby deleted in its entirety and amended to read as follows:

 

“During the Employment Period, the Executive shall receive an annual base salary at least equal  to Two Hundred Fifteen Thousand Two Hundred Fifty 10/100 ($215,250.10) (the “Annual Base Salary”), which shall be paid in accordance with the Company’s normal payroll practices for senior executive officers of the Company as in effect from time to time.”

 

3.                                      CONSTRUCTION.  Unless otherwise defined herein, capitalized terms shall have the meanings set forth in the Employment Agreement.  The terms of this Amendment amend and modify the Employment Agreement as if fully set forth in the Employment Agreement.  If there is any conflict between the terms, conditions and obligations of this Amendment and the Employment Agreement, this Amendment’s terms, conditions and obligations shall control.  All other provisions of the Employment Agreement not specifically modified by this Amendment are preserved.  This Amendment may be executed in counterparts (including via facsimile or .pdf), each of which shall be deemed an original, and all of which together shall constitute one and the same document.

 

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first written above.

 

	
THE EXECUTIVE:  
    	
THE COMPANY:  
    
	
 
    	
 
    
	
 
    	
 
    	
MACKINAC FINANCIAL   CORPORATION  
    
	
 
    	
 
    	
 
    
	
/s/ ERNIE R.   KRUEGER  
    	
 
    	
By: 
    	
/s/ PAUL D. TOBIAS  
    
	
ERNIE R. KRUEGER
    	
 
    	
Name: 
    	
Paul D. Tobias  
    
	
 
    	
 
    	
Title: 
    	
CEO and ChairmanExhibit 4.25

 

 

 

 

 

	 	  	 
	 	Can
    Fite Biopharma LTD.	 
	 	 	 
	 	THE
    2013 GLOBAL INCENTIVE OPTION SCHEME	 
	 	 	 

 

 

 

 

 

    	 

    	 

    

 

Can
Fite Biopharma Ltd. — 2013 Global Incentive Option Scheme

 

 

DEFINITIONS

 

For
purposes of the Global Incentive Option Scheme and related documents, including without limited, the Grant Notification Letter,
the following definitions shall apply:

 

	(a)	"Board" - the Board of Directors
    of the Company.
	 	 
	(b) 	"Cause" — any of the following:

 

(i)
conviction of any felony involving moral turpitude or affecting the Company or any of its affiliates;

 

(ii)
any refusal to carry out a reasonable directive of the chief executive
officer, the Board or the Grantee's direct supervisor, which involves the business of the Company or any of its affiliates and
was capable of being lawfully performed;

 

(iii)
embezzlement of funds of the Company or any
of its affiliates;

 

(iv)
any breach of the Grantee's fiduciary duties or duties of care of the Company or any of its affiliates; including without limitation
disclosure of confidential information of the Company or any of its affiliates;

 

(v)
any conduct (other than conduct in good faith), including without
limitation, any act or omission, reasonably determined by the Board to be materially detrimental to the Company or any of its
affiliates; and/or

 

(vi)
if and as such term is or may be defined under the Grantee's employment
agreement, service agreement or any other engagement agreement with the Company or any of its affiliates; and/or

 

(vii)
should circumstances arise as a result of which the Grantees' employment
with the Company and/or any of its affiliates is or may be terminated without severance pay.

 

For
the avoidance of any doubt, it is hereby clarified that in any event of conflict between the definition of the term "Cause"
in this Scheme and the definition of the term "Cause" in a certain employment agreement, the definition in this Scheme
shall prevail in connection with the Option, with the Grant Notification Letter and with this Scheme.

 

	(c)	"Chairman"
    - the chairman of the Committee.
	 	 
	(d)	"Committee" - a compensation
    committee appointed by the Board, which shall consist of no fewer than two members of the Board.
	 	 
	(e)	"Company" —Can
    Fite Biopharma Ltd., an Israeli company.
	 	 
	(f)	"Date of Grant" - the
    date of grant of an Option, as determined by the Board or the Committee and set forth in the Grantee's Grant Notification
    Letter.
	 	 
	(g)	"Employee" - a person
    who is employed by the Company or any affiliate.
	 	 
	(h)	"Expiration Date" - the
    date upon which an Option shall expire, as set forth in Section 7.2 of the Scheme.

 

    	2

    	 

    

 

Can
Fite Biopharma Ltd. — 2013 Global Incentive Option Scheme

 

	(i)	"Fair Market Value"
    - as of any date, the value of a Share determined as follows:

 

(i)
If the Shares are listed on any established Share exchange or a national market system, including without limitation the Tel-Aviv
Share Exchange, the NYSE MKT system, the NASDAQ National Market system, or the NASDAQ SmallCap Market of the NASDAQ Share Market,
the Fair Market Value shall be the closing sales price for such Shares (or the closing bid, if no sales were reported), as quoted
on such exchange or system for the last market trading day prior to time of determination, as reported in the Wall Street Journal,
or such other source as the Board deems reliable;

 

(ii)
If the Shares are regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value
shall be the mean between the high bid and low asked prices for the Shares on the last market trading day prior to the day of
determination, or;

 

(iii)
In the absence of an established market for the Shares, the Fair Market Value thereof shall be determined in good faith by the
Board.

 

	(j)	"Grantee"
    - a person who receives or holds an Option under the Scheme.
	 	 
	(k)	"Grant Notification Letter"
    - a document to be signed between the Company and a Grantee that sets out and inform the Grantee with respect to the terms
    and conditions of the grant of an Option.
	 	 
	(l)	"Non-Employee" - a
    director, consultant, advisor, service provider of the Company or any affiliate, or any other person who is not an Employee.
	 	 
	(m)	"Option" - an option
    to purchase one or more Shares of the Company pursuant to the Scheme.
	 	 
	(n)	"Purchase Price" -
    the price for each Share subject to an Option.
	 	 
	(o)	"Scheme" - this 2013
    Global Incentive Option Scheme.
	 	 
	(p)	"Share" - the ordinary
    shares, NIS 0.25 par value each, of the Company.
	 	 
	(q)	"Successor Company"
    - any entity the Company is merged to or is acquired by, in which the Company is not the surviving entity.
	 	 
	(r)	"Transaction" —
	 	 
	 	(i) Merger, acquisition or reorganization
    of the Company with one or more other entities in which the Company is not the surviving entity;
	 	 
	 	(ii) A
    sale of all or substantially all of the assets of the Company.
	 	 
	(s)	"Vested Option" -
    any Option, which has already been vested according to the Vesting Dates.
	 	 
	(t)	"Vesting Dates" -
    as determined by the Board or by the Committee, the date as of which the Grantee shall be entitled to exercise the Options
    or part of the Options, as set forth in Section 10 of the Scheme and in the Grantee's Grant Notification Letter.

 

    	3

    	 

    

 

Can
Fite Biopharma Ltd. — 2013 Global Incentive Option Scheme

 

THE
SCHEME

This
scheme, as amended from time to time, shall be known as Can Fite Biopharma Ltd. 2011 Global Incentive Option Scheme.

1.           
PURPOSE OF THE SCHEME

The
Scheme is intended to provide an incentive to retain, in the employ of the Company and its affiliates, persons of training, experience,
and ability, to attract new employees, directors, consultants, service providers and any other entity which the Board shall decide
their services are considered valuable to the Company, to encourage the sense of proprietorship of such persons, and to stimulate
the active interest of such persons in the development and financial success of the Company by providing them with opportunities
to purchase shares in the Company, pursuant to the Scheme.

Incentives
under the Scheme shall only be issued to Grantees subject to the applicable law in their respective country of residence for tax
purposes or any other purposes, as the case may be.

2.           
ADMINISTRATION OF THE SCHEME

 

		2.1	The Board shall have the power to administer the Scheme either directly or upon the recommendation
of the Committee, all as provided by applicable law and in the Company's Articles of Association. Notwithstanding the above, the
Board shall automatically have residual authority if no Committee shall be constituted or if such Committee shall cease to operate
for any reason.

		2.2	The Committee shall select one of its members as its Chairman and shall hold its meetings at such
times and places as the Chairman shall determine. The Committee shall keep records of its meetings and shall make such rules and
regulations for the conduct of its business as it shall deem advisable.

		2.3	The Board and/or the Committee, if applicable subject to the approval of the Board, to the extent
required under applicable law (and subject further to applicable laws) shall have the full power and authority to:

(i)
designate participants;

(ii) determine
the terms and provisions of the respective Grant Notification Letters, including, but not limited to, the number of Options
to be granted to each Grantee, the number of Shares to be covered by each Option, provisions concerning the time and the
extent to which the Options may be exercised and the nature and duration of restrictions as to the transferability or
restrictions constituting substantial risk of forfeiture and to cancel or suspend awards, as necessary;

(iii)
determine the Fair Market Value of the Shares covered by each Option;

(iv)
designate the type of Options; alter any restrictions and conditions of any
Options or Shares subject to any Options;

    	4

    	 

    

 

Can
Fite Biopharma Ltd. — 2013 Global Incentive Option Scheme

 

 

(v) alter any
restrictions and conditions of any Options or Shares subject to any Options;

(vi) interpret the provisions
and supervise the administration of the Scheme;

(vii) accelerate the
right of a Grantee to exercise in whole or in part, any previously granted Option;

(viii) determine
the Purchase Price of the Option;

(ix) prescribe, amend and
rescind rules and regulations relating to the Scheme; and

(x) make all
other deteuninations deemed necessary or advisable for the administration of the Scheme.

		2.4	The Board or the Committee shall have the authority to grant,
at its discretion, to the holder of an outstanding Option, in exchange for the surrender and cancellation of such Option,
a new Option having a purchase price equal to, lower than or higher than the Purchase Price of the original Option so surrendered
and canceled and containing such other terms and conditions, or to change the Purchase Price as the Board or the Committee may
prescribe in accordance with the provisions of the Scheme.

		2.5	Subject to the Company's Articles of Association, all decisions
and selections made by the Board or the Committee pursuant to the provisions of the Scheme shall be made by a majority of
its members except that no member of the Board or the Committee shall vote on, or be counted for quorum purposes, with respect
to any proposed action of the Board or the Committee relating to any Option to be granted to that member. Any decision reduced
to writing shall be executed in accordance with the provisions of the Company's Articles of Association, as the same may be in
effect from time to time.

		2.6	The interpretation and construction by the Committee of any provision of the Scheme or of any Grant
Notification Letter there under shall be final and conclusive unless otherwise determined by the Board.

		2.7	Subject to the Company's Articles of Association and the Company's decision, and to all approvals
legally required, including, but not limited to the provisions of any applicable law, each member of the Board or the Committee
shall be indemnified and held harmless by the Company against any cost or expense (including counsel fees) reasonably incurred
by him, or any liability (including any sum paid in settlement of a claim with the approval of the Company) arising out of any
act or omission to act in connection with the Scheme unless arising out of such member's own fraud or bad faith, to the extent
peitnitted by applicable law. Such indemnification shall be in addition to any rights of indemnification the member may have as
a director or otherwise under the Company's Articles of Association, any agreement, any vote of shareholders or disinterested directors,
insurance policy or otherwise.

3.               DESIGNATION
OF PARTICIPANTS

The persons eligible for
participation in the Scheme as Grantees shall include any Employees and/or Non-Employees of the Company or of any affiliate.

The grant of an Option
hereunder shall neither entitle the Grantee to participate nor disqualify the Grantee from participating in, any other grant of
Options pursuant to the Scheme or any other option or share plan of the Company or any of its affiliates.

    	5

    	 

    

 

Can
Fite Biopharma Ltd. — 2013 Global Incentive Option Scheme

 

 

4.         
 SHARES RESERVED FOR THE SCHEME; RESTRICTION THEREON

		4.1	The Company has reserved 966,634 authorized but unissued Shares, for the purposes of the
Scheme and for the purposes of any other share option plans which may be adopted by
the Company in the future, subject to adjustment as set forth in Section 6 below. Any Shares which remain unissued and which are
not subject to the outstanding Options at the termination of the Scheme shall cease to be reserved for the purpose of the Scheme,
but until termination of the Scheme the Company shall at all times reserve sufficient number of Shares to meet the requirements
of the Scheme. Should any Option for any reason expire or be canceled prior to its exercise or relinquishment in full, the Shares
subject to such Option may again be subjected to an Option under the Scheme or under the Company's other share option plans.

		4.2	Each Option granted pursuant to the Scheme, shall be
evidenced by a written Grant Notification Letter between the Company and the Grantee, in such
foful as the Board or the Committee shall from time to time approve. Each Grant Notification Letter shall state, among other matters,
the number of Shares to which the Option relates, the type of Option granted thereunder, the Vesting Dates, the Purchase Price
per share, the Expiration Date and such other terms and conditions as the Committee or the Board in its discretion may prescribe,
provided that they are consistent with this Scheme.

5.          
 PURCHASE PRICE

		5.1	The Purchase Price of each Share subject to an Option shall be determined by the Committee in its
sole and absolute discretion in accordance with applicable law, subject to any guidelines as may be determined by the Board from
time to time. Each Grant Notification Letter will contain the Purchase Price determined for each Grantee.

		5.2	Without derogating from the above and in addition thereto, the Purchase Price of each Share subject
to an Option shall be payable upon the exercise of an Option in the following acceptable forms of payment:

		(i)	cash, check or wire transfer;

 

	 	(ii)	at the discretion of the Committee, through delivery of Share (including other Share subject to the Options being exercised) having a Fair Market Value equal as of the date of exercise to the Purchase Price of the Share purchased and acquired upon the exercise of the Option, or by a different foun of cashless exercise method through a third party broker as approved by the Committee;

 

		(iii)	at the discretion of the Committee, any combination of the methods of payment permitted by any paragraph of this Section 5.2.

 

    	6

    	 

    

 

Can
Fite Biopharma Ltd. — 2013 Global Incentive Option Scheme

 

 

	 	5.3	The
Purchase Price shall be denominated in the currency of the primary economic environment of, either the Company or the Grantee (that
is the functional currency of the Company or the currency in which the Grantee is paid) as determined by the Company.

 

6.         ADJUSTMENTS

Upon the occurrence of
any of the following described events, Grantee's rights to purchase Shares under the Scheme shall be adjusted as hereafter provided:

		6.1	In the event of Transaction, the unexercised Options then outstanding under the Scheme shall be
assumed or substituted for an appropriate number of shares of each class of shares or other securities of the Successor Company
(or a parent or subsidiary of the Successor Company) as were distributed to the shareholders of the Company in connection and with
respect to the Transaction. In the case of such assumption and/or substitution of Options, appropriate adjustments shall be made
to the Purchase Price so as to reflect such action and all other terms and conditions of the Grant Notification Letters shall remain
unchanged, including but not limited to the vesting schedule, all subject to the deteunination of the Committee or the Board, which
determination shall be in their sole discretion and final. The Company shall notify the Grantee of the Transaction in such form
and method as it deems applicable at least 7 days prior to the effective date of such Transaction.

		6.2	Notwithstanding the above and subject to any applicable law, the Board or the Committee shall
have full power and authority to determine that in certain Grant Notification Letters there shall be a clause instructing that,
if in any such Transaction as described in Section 6.1 above, the Successor Company (or parent or subsidiary of the Successor Company)
does not agree to assume or substitute for the Options, the Vesting Dates shall be accelerated so that any unvested Option or any
portion thereof shall be immediately vested as of the date which is 7 days prior to the effective date of the Transaction.

		6.3	For the purposes of Section 6.1 above, an Option shall be considered assumed or substituted
if, following the Transaction, the Option confers the right to purchase or receive, for each Share underlying an Option immediately
prior to the Transaction, the consideration (whether shares, options, cash, or other securities or property) received in the Transaction
by holders of shares held on the effective date of the Transaction (and if such holders were offered a choice of consideration,
the type of consideration chosen by the holders of a majority of the outstanding shares); provided, however, that if such consideration
received in the Transaction is not solely ordinary shares (or their equivalent) of the Successor Company or its parent or subsidiary,
the Committee may, with the consent of the Successor Company, provide for the consideration to be received upon the exercise of
the Option to be solely ordinary shares (or their equivalent) of the Successor Company or its parent or subsidiary equal in Fair
Market Value to the per Share consideration received by holders of a majority of the outstanding shares in the Transaction; and
provided further that the Committee may determine, in its discretion, that in lieu of such assumption or substitution of Options
for options of the Successor Company or its parent or subsidiary, such Options will be substituted for any other type of
asset or property including cash which is fair under the circumstances.

 

    	7

    	 

    

 

Can
Fite Biopharma Ltd. — 2013 Global Incentive Option Scheme

 

 

		6.4	The Board or the Committee shall have full power and authority
to determine that in certain Grant Notification Letters there shall be a clause instructing
that, if the Company is voluntarily liquidated or dissolved while unexercised Options remain outstanding under the Scheme, the
Company shall immediately notify all unexercised Option holders of such liquidation, and the Option holders shall then have 7 days
to exercise any unexercised Vested Option held by them at that time, in accordance with the exercise procedure set forth herein.
Upon the expiration of such 7 days period, all remaining outstanding Options will terminate immediately.

		6.5	If the outstanding shares of the Company shall at any time
be changed or exchanged by declaration of a cash dividend, share dividend (bonus shares),
distribution of subscription rights, share split, combination or exchange of shares, recapitalization, spin-off or any other like
event by or of the Company, and as often as the same shall occur, then the number, class and kind of the Shares subject to the
Scheme or subject to any Options therefore granted, and the Purchase Prices, shall be appropriately and equitably adjusted so as
to maintain the proportionate number of Shares without changing the aggregate Purchase Price. Upon happening of any of the foregoing,
the class and aggregate number of Shares issuable pursuant to the Scheme (as set forth in Section 6 hereof), in respect of which
Options have not yet been exercised, shall be appropriately adjusted, all as will be determined by the Board whose determination
shall be final.

7.             TERM
AND EXERCISE OF OPTIONS

		7.1	Options shall be exercised by the
                                         Grantee by giving written notice to the Company and/or to any third party designated
                                         by the Company (the: "Representative"), in such form and method as may
                                         be determined by the Company, which exercise shall be effective upon receipt of such
                                         notice by the Company and/or the Representative and the payment of the Purchase Price
                                         at the Company's or the Representative's principal office. The notice shall specify the
                                         number of Shares with respect to which the Option is being exercised.

		7.2	Options, to the extent not previously exercised, shall terminate forthwith upon the earlier of:
(i) the date set forth in the Grant Notification Letter; (ii) the expiration of any extended period in any of the events set forth
in Section 7.5 below, or (iii) ten (10) years from their Date of Grant.

		7.3	The Options may be exercised by the Grantee in whole at any time or in part from time to time,
to the extent that the Options become vested and exercisable, prior to the Expiration Date, and provided that, subject to the provisions
of Section 7.5 below, the Grantee is employed by or providing services to the Company or any of its affiliates, at all times during
the period beginning with the granting of the Option and ending upon the date of exercise.

 

    	8

    	 

    

 

Can
Fite Biopharma Ltd. — 2013 Global Incentive Option Scheme 

 

 

	 	7.4	Subject
    to the provisions of Section 7.5 below, in the event of termination of Grantee's employment or services, with the Company
    or any of its affiliates, all Options granted to such Grantee will immediately expire. A notice of termination of employment
    or service shall be deemed to constitute termination of employment or service. For the avoidance of doubt, in case of such
    termination of employment or service, the unvested portion of the Grantee's Option shall not vest and shall not become exercisable
    and the Grantee shall have no claim against the Company and/or its affiliate that his/her Options were prevented from continuing
    to vest as of such termination. Notwithstanding anything to the contrary mentioned above, a Grantee shall not cease to be
    an Employee only due to the transfer of such Employee's employment among the Company and its affiliates.

 

	 	7.5	Notwithstanding
    anything to the contrary hereinabove and unless otherwise determined in the Grantee's Grant Notification Letter, an Option
    may be exercised after the date of termination of Grantee's employment or service with the Company or any affiliates during
    an additional period of time beyond the date of such termination, but only with respect to the number of Vested Options at
    the time of such termination according to the Vesting Dates, if:

 

	 		(i)	termination
                                         is without Cause, in which event any Vested Option still in force and unexpired may be
                                         exercised within a period of ninety (90) days after the date of such termination; or-
	 	 	 	 
	 		(ii)	termination
                                         is the result of death or disability of the Grantee, in which event any Vested Option
                                         still in force and unexpired may be exercised within a period of twelve (12) months after
                                         the date of such termination; or -
	 	 	 	 
	 		(iii)	prior
                                         to the date of such termination, the Committee shall authorize an extension of the terms
                                         of all or part of the Vested Options beyond the date of such termination for a period
                                         not to exceed the period during which the Options by their terms would otherwise have
                                         been exercisable.

 

For
avoidance of any doubt, if termination of employment or service is for Cause, any outstanding unexercised Option (whether vested
or non-vested), will immediately expire and terminate, and the Grantee shall not have any right in connection to such outstanding
Options.

 

	 	7.6	Any
    form of Grant Notification Letter authorized by the Scheme may contain such other provisions as the Committee may, from time
    to time, deem advisable.

 

	 	7.7	The
    Options and any underlying Shares are extraordinary, one-time benefits granted to the Grantee and are not and shall not be
    deemed a salary component for any purpose whatsoever, including in connection with calculating severance compensation under
    applicable law.

 

	 	7.8	Neither
    the Grantee nor any other person, as the case may be, shall have any claim to be granted any Options, and there is no obligation
    by the Company for uniformity of treatment of Grantees or their beneficiaries (if applicable). The terms and conditions of
    the Options granted under this Scheme and any of the Board's determinations and interpretations with respect thereto need
    not be the same with respect to each Grantee

 

    	9

    	 

    

 

Can
Fite Biopharma Ltd. - 2013 Global Incentive Option Scheme

 

 

(whether
or not such Grantees are similarly situated).

 

	8.	VESTING
    OF OPTIONS

 

	 	8.1	Subject
    to the provisions of the Scheme, each Option shall vest following the Vesting Dates and for the number of Shares as shall
    be provided in the Grant Notification Letter. However, no Option shall be exercisable after the Expiration Date.

 

	 	8.2	An
    Option may be subject to such other terms and conditions on the time or times when it may be exercised, as the Committee may
    deem appropriate. The vesting provisions of individual Options may vary.

 

	9.	DIVIDENDS

 

With
respect to all Shares (but excluding, for avoidance of any doubt, any unexercised Options) allocated or issued upon the exercise
of Options purchased by the Grantee and held by the Grantee or by the Trustee, as the case may be, the Grantee shall be entitled
to receive dividends in accordance with the quantity of such Shares, subject to the provisions of the Company's Articles of Association
(and all amendments thereto) and subject to any applicable taxation on distribution of dividends.

 

	10.	PURCHASE
    FOR INVESTMENT

 

The
Company's obligation to issue or allocate Shares upon exercise of an Option granted under the Scheme is expressly conditioned
upon:

 

		(i)	the
                                         Company's completion of any registration or other qualifications of such Shares under
                                         all applicable laws, rules and regulations, or;
		(ii)	representations
                                         and undertakings by the Grantee (or his legal representative, heir or legatee, in the
                                         event of the Grantee's death) to assure that the sale of the Shares complies with any
                                         registration exemption requirements which the Company in its sole discretion shall deem
                                         necessary or advisable.

 

Such
required representations and undertakings may include representations and agreements that such Grantee (or his legal representative,
heir, or legatee):

 

		(i)	is
                                         purchasing such Shares for investment and not with any present intention of selling or
                                         otherwise disposing thereof; and;
		(ii)	agrees
                                         to have placed upon the face and reverse of any certificates evidencing such Shares a
                                         legend setting forth (a) any representations and undertakings which such Grantee has
                                         given to the Company or a reference thereto, and (b) that, prior to effecting any sale
                                         or other disposition of any such Shares, the Grantee must furnish to the Company an opinion
                                         of counsel, satisfactory to the Company, that such sale or disposition will not violate
                                         the applicable laws, rules and regulations of the United States or any other state having
                                         jurisdiction over the Company and the Grantee.

 

    	10

    	 

    

 

Can
Fite Biopharma Ltd. - 2013 Global Incentive Option Scheme

 

 

	11.	RESTRICTIONS
    ON ASSIGNABILITY AND SALE OF OPTIONS

 

No
Option or any right with respect thereto, purchasable hereunder, whether fully paid or not, shall be assignable, transferable
or given as collateral or any right with respect to it given to any third party whatsoever, other than by will or by laws of decent
and distribution, or as specifically otherwise allowed under the Scheme, except as specifically allowed under the Scheme, and
during the lifetime of the Grantee each and all of such Grantee's rights to purchase Shares hereunder shall be exercisable only
by the Grantee.

 

Any
such action made directly or indirectly, for an immediate validation or for a future one, shall be void.

 

	12.	EFFECTIVE DATE,
    DURATION, AMENDMENTS OR TERMINATION OF THE SCHEME

 

	 	12.1	The
    Scheme shall be effective as of the day it was adopted by the Board and shall teaninate at the end of ten (10) years from
    such day of adoption (the: "Termination Date").

 

	 	12.2	The
    Company shall obtain the approval of the Company's shareholders for the adoption of this Scheme and/or the Annexes thereto,
    or for any amendment to this Scheme and/or the Annexes thereto, if shareholders' approval is required under any applicable
    law including without limitation the U.S. securities law or the securities laws of other jurisdiction applicable to Options
    granted to Grantees under this Scheme and/or the Annexes thereto, or if shareholders' approval is required by any authority
    or by any governmental agencies or national securities exchanges including without limitation the U.S. Securities and Exchange
    Commission.

 

	 	12.3	The
    Board may at any time, subject to the provisions of Section 12.2 above and all applicable law, amend, alter, suspend or terminate
    the Scheme, provided, however, that

 

		(i)	the
                                         Board may not extend the term of the Scheme specified in Section 12.1 above and;
	 	 	 
		(ii)	no
                                         amendment, alteration, suspension or termination of the Scheme shall impair the rights
                                         of any Grantee, unless mutually agreed otherwise by the Grantee and the Company, which
                                         agreement must be in writing and signed by the Grantee and the Company.

 

Earlier
termination of the Scheme prior to the Termination Date shall not affect the Board's ability to exercise the powers granted to
it hereunder with respect to Options granted under the Scheme prior to the date of such earlier termination.

 

    	11

    	 

    

 

Can
Fite Biopharma Ltd. — 2013 Global Incentive Option Scheme

 

 

	13.	GOVERNMENT
    REGULATIONS

 

The
Scheme, and the granting and exercise of Options hereunder, and the obligation of the Company to sell and deliver Shares under
such Options, shall be subject to all applicable laws, rules, and regulations, whether of the State of Israel or of the United
States or any other State having jurisdiction over the Company and the Grantee, including the registration of the Shares under
the United States Securities Act of 1933, and the Ordinance and to such approvals by any governmental agencies or national securities
exchanges as may be required. Nothing herein shall be deemed to require the Company to register the Shares under the securities
laws of any jurisdiction.

 

	14.	CONTINUANCE
    OF EMPLOYMENT OR HIRED SERVICES

 

Neither
the Scheme nor the Grant Notification Letter with the Grantee shall impose any obligation on the Company or an Affiliate thereof,
to continue any Grantee in its employ or service, and nothing in the Scheme or in any Option granted pursuant thereto shall confer
upon any Grantee any right to continue in the employ or service of the Company or an Affiliate thereof or restrict the right of
the Company or an Affiliate thereof to terminate such employment or service at any time.

 

	15.	GOVERNING
    LAW & JURISDICTION

 

The
Scheme shall be governed by and construed and enforced in accordance with the laws of the State of Israel applicable to contracts
made and to be performed therein, without giving effect to the principles of conflict of laws. The competent courts of Tel-Aviv,
Israel shall have sole jurisdiction in any matters pertaining to the Scheme.

 

	16.	TAX
    CONSEQUENCES

 

	 	16.1	Any
    tax consequences to any Grantee arising from the grant or exercise of any Option, from the payment for Shares covered thereby
    or from any other event or act (of the Company and/or its affiliates, or the Grantee) hereunder shall be borne solely by the
    Grantee. The Company and/or its affiliates shall withhold taxes according to the requirements under the applicable laws, rules,
    and regulations, including withholding taxes at source. Furthermore, the Grantee shall agree to indemnify the Company and/or
    its affiliates and hold them harmless against and from any and all liability for any such tax or interest or penalty thereon,
    including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any
    payment made to the Grantee.

 

	 	16.2	The
    Company shall not be required to release any Share certificate to a Grantee until all required payments have been fully made.

 

    	12

    	 

    

 

Can
Fite Biopharma Ltd. — 2013 Global Incentive Option Scheme

 

 

	17.	NON-EXCLUSIVITY
    OF THE SCHEME

 

The
adoption of the Scheme by the Board shall not be construed as amending, modifying or rescinding any previously approved incentive
arrangements or as creating any limitations on the power of the Board to adopt such other incentive arrangements as it may deem
desirable, including, without limitation, the granting of Options otherwise than under the Scheme, and such arrangements may be
either applicable generally or only in specific cases.

 

For
the avoidance of doubt, prior grant of options to Grantees of the Company under their employment agreements, and not in the framework
of any previous option scheme, shall not be deemed an approved incentive arrangement for the purpose of this Section.

 

	18.	MULTIPLE
    AGREEMENTS

 

The
terms of each Option may differ from other Options granted under the Scheme at the same time, or at any other time. The Board
may also grant more than one Option to a given Grantee during the term of the Scheme, either in addition to, or in substitution
for, one or more Options previously granted to that Grantee.

 

	19.	RULES
    PARTICULAR TO SPECIFIC COUNTRIES

 

Notwithstanding
anything herein to the contrary, the terms and conditions of the Scheme may be adjusted with respect to a particular country by
means of an addendum to the Scheme in the form of an annex (the: "Annex"), and to the extent that the terms and conditions
set forth in the Annex conflict with any provisions of the Scheme, the provisions of the Annex shall govern. Terms and conditions
set forth in the Annex shall apply only to Options issued to Grantees under the jurisdiction of the specific country that is subject
of the Annex and shall not apply to Options issued to any other Grantee. The adoption of any such Annex shall be subject to the
approval of the Board and if required the approval of the shareholders of the Company.

 

*****

 

    	13

    	 

    

 

 

 

 

 

CAN-FITE
BIOPHARMA LTD.

 

ANNEX
A - ISRAEL

TO
THE 2013 GLOBL INCENTIVE OPTION SCHEME

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 

    	 

    

 

Can-Fite
Biopharma Ltd. — Israeli Annex

 

DEFINITIONS

 

For
purposes of this Annex and the Grant Notification Letter, the following definitions shall apply:

 

		(a)	"Affiliate"
                                         - any "employing company" within the meaning of Section 102(a) of the Ordinance.
	 	 	 
		(b)	"Approved
                                         102 Option" - an Option granted pursuant to Section 102(b) of the Ordinance
                                         and held in trust by a Trustee for the benefit of the Grantee.
	 	 	 
		(c)	"Capital
                                         Gain Option (CGO)" - an Approved 102 Option elected and designated by the Company
                                         to qualify under the capital gain tax treatment in accordance with the provisions of
                                         Section 102(b)(2) of the Ordinance.
	 	 	 
		(d)	"Controlling
                                         Shareholder" - shall have the meaning ascribed to it in Section 32(9) of the
                                         Ordinance.
	 	 	 
		(e)	"Employee"
                                         - a person who is employed by the Company or its Affiliates, including an individual
                                         who is serving as a director or an office holder, but excluding any Controlling Shareholder,
                                         all as determined in Section 102 of the Ordinance.
	 	 	 
		(f)	"ITA"
                                         - the Israeli Tax Authorities.
	 	 	 
		(g)	"Non-Employee"
                                         - a consultant, adviser, service provider, Controlling Shareholder or any other person
                                         who is not an Employee.
	 	 	 
		(h)	"Ordinary
                                         Income Option (010)" - an Approved 102 Option elected and designated by the
                                         Company to qualify under the ordinary income tax treatment in accordance with the provisions
                                         of Section 102(b)(1) of the Ordinance.
	 	 	 
		(i)	"102
                                         Option" - any Option granted to Employees pursuant to Section 102 of the Ordinance.
	 	 	 
	 	(j)	"3(i)
                                         Option" - an Option granted pursuant to Section 3(i) of the Ordinance to any
                                         person who is a Non-Employee.
	 	 	 
	 	(j)	"Ordinance"
                                         - the Israeli Income Tax Ordinance [New Version] 1961 as now in effect or as hereafter
                                         amended.
	 	 	 
	 	(k)	"Section
                                         102" - Section 102 of the Ordinance and any regulations, rules, orders or procedures
                                         promulgated thereunder as now in effect or as hereafter amended.
	 	 	 
	 	(l)	"Trustee"
                                         - any individual appointed by the Company to serve as a trustee and approved by the
                                         ITA, all in accordance with the provisions of Section 102(a) of the Ordinance.

 

    	- 2 -

    	 

    

 

Can-Fite
Biopharma Ltd. — Israeli Annex

 

	 	(n)	"Unapproved
    102 Option" - an Option granted pursuant to Section 102(c) of the Ordinance and not held in trust by a Trustee.

 

For
the avoidance of any doubt, it is hereby clarified that any capitalized terms not specifically defined in this Annex shall be
construed according to the interpretation given to it in the Scheme.

 

    	- 3 -

    	 

    

 

Can-Fite
Biopharma Ltd. — Israeli Annex

 

ANNEX
A - ISRAEL

 

	1.	GENERAL

 

	 	1.1	This
    Annex (the: "Annex") shall apply only to Grantees who are residents of the state of Israel at the Date of
    Grant or those who are deemed to be residents of the state of Israel for the payment of tax at the Date of Grant. The provisions
    specified hereunder shall form an integral part of the 2013 Global Incentive Option Scheme of Can-Fite Biopharma Ltd. (hereinafter:
    the "Scheme"), which applies to the issuance of options to purchase Shares of Can-Fite Biophauna Ltd. (hereinafter:
    the "Company"). According to the Scheme, options to purchase the Company's Shares may be issued to employees,
    directors, consultants and service provides of the Company or its affiliates.
	 	 	 
	 	1.2	This
    Annex is effective with respect to Options granted following Amendment no. 132 of the Ordinance, which entered into force
    on January 1, 2003.
	 	 	 
	 	1.3	This
    Annex is to be read as a continuation of the Scheme and only modifies options granted to Israeli Grantees so that they comply
    with the requirements set by the Israeli law in general, and in particular with the provisions of Section 102 (as specified
    herein), as may be amended or replaced from time to time. For the avoidance of doubt, this Annex does not add to or modify
    the Scheme in respect of any other category of Grantees.
	 	 	 
	 	1.4	The
    Scheme and this Annex are complimentary to each other and shall be deemed as one. In any case of contradiction, whether explicit
    or implied, between the provisions of this Annex and the Scheme, the provisions set out in the Annex shall prevail.

 

	2.	ISSUANCE
    OF OPTIONS

 

	 	2.1	The
    persons eligible for participation in the Scheme as Grantees shall include any Employees and/or Non-Employees of the Company
    or of any Affiliate; provided, however, that (i) Employees may only be granted 102 Options; and (ii) Non-Employees and/or
    Controlling Shareholders may only be granted 3(i) Options.
	 	 	 
	 	2.2	The
    Company may designate Options granted to Employees pursuant to Section 102 as Unapproved 102 Options or Approved 102 Options.
	 	 	 
	 	2.3	The
    grant of Approved 102 Options shall be made under this Annex adopted by the Board, and shall be conditioned upon the approval
    of this Annex by the ITA.
	 	 	 
	 	2.4	Approved
    102 Options may either be classified as Capital Gain Options ("CGOs") or Ordinary Income Options ("OIOs").

 

    	- 4 -

    	 

    

 

Can-Fite
Biopharma Ltd. — Israeli Annex

 

	 	2.5	No
    Approved 102 Options may be granted under this Annex to any eligible Employee, unless and until, the Company's election of
    the type of Approved 102 Options as CGO or OM granted to Employees (the: "Election"), is appropriately filed
    with the ITA. Such Election shall become effective beginning the first date of grant of an Approved 102 Option under this
    Annex and shall remain in effect at least until the end of the year following the year during which the Company first granted
    Approved 102 Options. The Election shall obligate the Company to grant only the type of Approved 102 Option it has
    elected, and shall apply to all Grantees who were granted Approved 102 Options during the period indicated herein, all in
    accordance with the provisions of Section 102(g) of the Ordinance For the avoidance of doubt, such Election shall not prevent
    the Company from granting Unapproved 102 Options simultaneously.
	 	 	 
	 	2.6	All
    Approved 102 Options must be held in trust by a Trustee, as described in Section 3 below.
	 	 	 
	 	2.7	For
    the avoidance of doubt, the designation of Unapproved 102 Options and Approved 102 Options shall be subject to the terms and
    conditions set forth in Section 102.
	 	 	 
	 	2.8	Implementation
    of the mechanisms set out in Sections 2.4 and 5.2(ii) of the Scheme shall require the obtaining of a tax ruling from ITA.

 

	3.	TRUSTEE

 

	 	3.1	Approved
    102 Options which shall be granted under this Annex and/or any Shares allocated or issued upon exercise of such Approved 102
    Options and/or other shares received subsequently following any realization of rights, including without limitation bonus
    shares, shall be allocated or issued to the Trustee and held for the benefit of the Grantees for such period of time as required
    by Section 102 or any regulations, rules or orders or procedures promulgated thereunder (the: "Holding Period").
    In the case the requirements for Approved 102 Options are not met, the Approved 102 Options may be regarded as Unapproved
    102 Options, all in accordance with the provisions of Section 102.
	 	 	 
	 	3.2	Notwithstanding
    anything to the contrary, the Trustee shall not release any Shares allocated or issued upon exercise of Approved 102 Options
    prior to the full payment of the Grantee's tax liabilities arising from Approved 102 Options which were granted to him and/or
    any Shares allocated or issued upon exercise of such Options.
	 	 	 
	 	3.3	With
    respect to any Approved 102 Option, subject to the provisions of Section 102 and any rules or regulation or orders or procedures
    promulgated thereunder, a Grantee shall not sell or release from trust any Share received upon the exercise of an Approved
    102 Option and/or any share received subsequently following any realization of rights, including without limitation, bonus
    shares, until the lapse of the Holding Period required under Section 102 of the Ordinance. Notwithstanding the above, if any
    such sale or release occurs during the Holding Period, the sanctions under Section 102 of the Ordinance and under any rules
    or regulation or orders or procedures promulgated thereunder shall apply to and shall be borne by such Grantee.

 

    	- 5 -

    	 

    

 

Can-Fite
Biopharma Ltd. — Israeli Annex

 

	 	3.4	Upon
    receipt of Approved 102 Option, the Grantee will sign an undertaking in which he or she will give his or her consent
    to the grant of the Option under Section 102, and will undertake to comply with the terms of Section 102 and the trust agreement
    between the Company and the Trustee.

 

	4.	THE
    OPTIONS

 

		The
    erms and conditions, upon which the Options shall be issued and exercised, shall be as specified in the Grant Notification
    Letter to be executed pursuant to the Scheme and to this Annex. Each Grant Notification Letter shall state, inter alia, the
    number of Shares to which the Option relates, the type of Option granted thereunder (whether a CGO, OIO, Unapproved 102 Option
    or a 3(i) Option), the vesting provisions and the Purchase Price.

 

	5.	FAIR MARKET VALUE

 

		Without
    derogating from the definition of "Fair Market Value" enclosed in the Scheme and solely for the purpose of
    determining the tax liability pursuant to Section 102(b)(3) of the Ordinance, if at the date of grant the Company's shares
    are listed on any established stock exchange or a national market system or if the Company's shares will be registered for
    trading within ninety (90) days following the date of grant of the CGOs, the fair market value of the Shares at the date of
    grant shall be deteimined in accordance with the average value of the Company's shares on the thirty (30) trading days preceding
    the date of grant or on the thirty (30) trading days following the date of registration for trading, as the case may be.

 

	6.	EXERCISE OF OPTIONS

 

	 	6.1	Options shall be exercised by the Grantee by giving
    a written notice to the Company and/or to any third party designated by the Company (the: "Representative"),
    in such form and method as may be determined by the Company and, when applicable, by the Trustee, in accordance with the requirements
    of Section 102, which exercise shall be effective upon receipt of such notice by the Company and/or the Representative and
    the payment of the Purchase Price for the number of Shares with respect to which the option is being exercised, at the Company's
    or the Representative's principal office. The notice shall specify the number of Shares with respect to which the option is
    being exercised.

 

	 	6.2	Without derogating from Section 4.2 of the Scheme,
    and in addition thereto, with respect to Approved 102 Options, any shares of Common Stock allocated or issued upon the exercise
    of an Approved 102 Option, shall be voted in accordance with the provisions of Section 102 and any rules, regulations or orders
    promulgated thereunder.

 

	7.	ASSIGNABILITY
    AND SALE OF OPTIONS

 

	 	7.1	Notwithstanding any other provision of the Scheme,
    no Option or any right with respect thereto, purchasable hereunder, whether fully paid or not, shall be assignable, transferable
    or given as collateral or any right with respect to them given to any third party whatsoever, and during the lifetime of the
    Grantee each and all of such Grantee's rights to purchase Shares hereunder shall be exercisable only by the Grantee.

  

    	- 6 -

    	 

    

 

Can-Fite
Biopharma Ltd. — Israeli Annex

 

	 		Any
    such action made directly or indirectly, for an immediate validation or for a future one, shall be void.

 

	 	7.2	As
    long as Options or Shares purchased pursuant to thereto are held by the Trustee on behalf of the Grantee, all rights
    of the Grantee over the shares are personal, can not be transferred, assigned, pledged or mortgaged, other than by will or
    laws of descent and distribution.

 

	8.	INTEGRATION
    OF SECTION 102 AND TAX ASSESSING OFFICER'S PERMIT

 

	 	8.1	With
    regards to Approved 102 Options, the provisions of the Scheme and/or the Annex and/or the Grant Notification Letter shall
    be subject to the provisions of Section 102 and the Tax Assessing Officer's permit, and the said provisions and permit shall
    be deemed an integral part of the Scheme and of the Annex and of the Grant Notification Letter.

 

	 	8.2	Any provision of Section 102 and/or the said permit
    which is necessary in order to receive and/or to keep any tax benefit pursuant to Section 102, which is not expressly specified
    in the Scheme or the Annex or the Grant Notification Letter, shall be considered binding upon the Company and the Grantees.

 

	9.	DIVIDEND

 

		Subject
    to the Company's Articles of Association, with respect to all Shares (but excluding, for avoidance of any doubt, any unexercised
    options) allocated or issued upon the exercise of Options and held by the Grantee or by the Trustee as the case may be, the
    Grantee shall be entitled to receive dividends in accordance with the quantity of such shares, and subject to any applicable
    taxation on distribution of dividends, and when applicable subject to the provisions of Section 102 and the rules, regulations
    or orders promulgated thereunder.

 

	10.	TAX CONSEQUENCES

 

	 	10.1	Any
    tax consequences arising from the grant or exercise of any Option, from the payment for Shares covered thereby or from any
    other event or act (of the Company, and/or its Affiliates, and the Trustee or the Grantee), hereunder, shall be borne solely
    by the Grantee. The Company and/or its Affiliates, and/or the Trustee shall withhold taxes according to the requirements under
    the applicable laws, rules, and regulations, including withholding taxes at source. Furthermore, the Grantee shall agree to
    indemnify the Company and/or its Affiliates and/or the Trustee and hold them harmless against and from any and all liability
    for any such tax or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold,
    or to have withheld, any such tax from any payment made to the Grantee.

 

	 	10.2	The
    Company and/or, when applicable, the Trustee shall not be required to release any share certificate to a Grantee until all
    required payments have been fully made.

 

	 	10.3	With
    respect to Unapproved 102 Option, if the Grantee ceases to be employed by the Company or any Affiliate, the Grantee shall
    extend to the Company and/or its Affiliate a security or guarantee for the payment of tax due at the time of sale of Shares,
    all in accordance with the provisions of Section 102 and the
    rules, regulation or orders promulgated thereunder.

 

    	- 7 -

    	 

    

 

Can-Fite
Biopharma Ltd. — Israeli Annex

 

	11.	GOVERNING
    LAW & JURISDICTION

 

	
	This
    Annex shall be governed by and construed and enforced in accordance with the laws of the State of Israel applicable to contracts
    made and to be performed therein, without giving effect to the principles of conflict of laws. The competent courts of Tel-Aviv,
    Israel shall have sole jurisdiction in any matters pertaining to this Annex.

 

*
* *

    	- 8 -

    	 

    

 

 

 

Attn.:
[Grantee's name, I.D. #, address].

 

Subject:
Israeli Grant Notification Letter

 

	1.	The
                                         Company has decided to grant you Options under the Can-fite Biopharma Ltd. 2013 Global
                                         Incentive Option Scheme (the: "Scheme") and Annex A — Israel to
                                         the Scheme (the: "Israeli Annex"), duly adopted and approved on November
                                         28, 2013, a copy of which is attached as Exhibit A hereto, forming an integral
                                         part hereof Unless otherwise defined herein, capitalized terms used herein shall have
                                         the meaning ascribed to them in the Scheme and in the Israeli Annex.
	 	 
	2.	The
                                         terms of the Option shall commence on the Date of Grant and terminate at the Expiration
                                         Date, or at the time at which the Options expire pursuant to the terms of the Scheme
                                         and Israeli Annex and as set forth in Exhibit B hereto.
	 	 
	3.	The
                                         number of Options granted to you as set forth in Exhibit B hereto shall be exercisable
                                         for one Share, upon payment of the Purchase Price as set forth in Exhibit B. The
                                         Options may be exercised only to purchase whole Shares, and in no case may a fraction
                                         of a Share be purchased. If any fractional Share would be deliverable upon exercise,
                                         such fraction shall be rounded up one-half or less, or otherwise rounded down, to the
                                         nearest whole number.
	 	 
	4.	Subject
                                         to the provisions of the Scheme, your Options shall vest and become exercisable according
                                         to the Vesting Dates as set forth in Exhibit B hereto, provided that you are employed
                                         by or providing services to the Company and/or its Affiliates on the applicable Vesting
                                         Date.
	 	 
	 	For
                                         the avoidance of any doubt, you hereby acknowledge that any and all unexercised Options
                                         granted to you shall terminate and shall no longer be exercisable on the Expiration Date.
	 	 
	5.	You
                                         may exercise your Options in accordance with the provisions of Section 7.1 of the Scheme
                                         and Section 6 of the Israeli Annex.
	 	 
	6.	Notwithstanding
                                         anything to the contrary in Section 6.1 of the Scheme and in addition thereto, if in
                                         any such Transaction as described in Section 6.1 of the Scheme, the Successor Company
                                         (or parent or subsidiary of the Successor Company) does not agree to assume or substitute
                                         your Options, the Vesting Dates shall be accelerated so that any of your unvested Option
                                         shall be immediately vested in full as of the date which is 7 days prior to the effective
                                         date of the Transaction, and the Committee shall notify you that the unexercised Options
                                         are fully exercisable for a period of 7 days from the date of such notice, and that any
                                         of your unexercised Options shall terminate upon the expiration of such period.
	 	 
	 	It
                                         is also resolved that if the Successor Company (or parent or subsidiary of the Successor
                                         Company) agrees to assume or substitute your Options and your employment with the Successor
                                         Company is terminated by the Successor Company without "Cause" within one year
                                         of the closing of the Transaction, your Vesting Dates shall be accelerated so that any
                                         of your unvested portion of the substituted Option shall be immediately vested in full
                                         as of the date of such termination without Cause.

 

 

    	 

    	 

    

 

	7.	You
                                         accept and agree that with respect to any Approved 102 Option granted to you, subject
                                         to the provisions of Section 102 and any rules or regulation or orders or procedures
                                         promulgated thereunder, you shall not sell or release from trust any Share received by
                                         you upon the exercise of an Approved 102 Option and/or any share received subsequently
                                         following any realization of rights, including without limitation, bonus shares, until
                                         the lapse of the Holding Period required under Section 102 of the Ordinance. Notwithstanding
                                         the above, you are aware that if any such sale or release occurs during the Holding Period,
                                         the sanctions under Section 102 of the Ordinance and under any rules or regulation or
                                         orders or procedures promulgated thereunder shall apply to you and shall be borne by
                                         you.
	 	 
	 	With
respect to Approved 102 Options, you hereby acknowledge that you are familiar with the provisions of Section 102 and the regulations
and rules promulgated thereunder, including without limitations the type of Option granted to you hereunder and the tax implications
applicable to such grant. You accept the provisions of the trust agreement signed between the Company and the Trustee, attached
as Exhibit C hereto, and agree to be bound by its terms.

 

	8.	Should
                                         any Unapproved 102 Option be granted to you, you hereby agree that should you ceases
                                         to be employed by the Company or any Affiliate, you shall extend to the Company and/or
                                         its Affiliate a security or guarantee for the payment of tax due at the time of sale
                                         of Shares, all in accordance with the provisions of Section 102 and the rules, regulation
                                         or orders promulgated thereunder.
	 	 
	9.	By
                                         signing this Grant Notification Letter you are aware and agree that any tax consequences
                                         arising from the grant or exercise of any Option, from the payment for Shares covered
                                         thereby or from any other event or act (of the Company and/or its Affiliates, the Trustee
                                         or yourself), hereunder, shall be borne solely by you. The Company and/or its Affiliates
                                         and/or the Trustee shall withhold taxes according to the requirements under the applicable
                                         laws, rules, and regulations, including withholding taxes at source. Furthermore, you
                                         hereby accept to indemnify the Company and/or its Affiliates and/or the Trustee and hold
                                         them harmless against and from any and all liability for any such tax or interest or
                                         penalty thereon, including without limitation, liabilities relating to the necessity
                                         to withhold, or to have withheld, any such tax from any payment made to you.
	 	 
	 	You
will not be entitled to receive from the Company and/or the Trustee any Shares allocated or issued upon the exercise of your Options
prior to the full payments of your tax liabilities arising from Options which were granted to you and/or Shares issued upon the
exercise of Options. For the avoidance of doubt, neither the Company nor the Trustee shall be required to release any share certificate
to you until all payments required to be made by you have been fully satisfied.
	 	 
	 	Please
note that the receipt of the Options and the acquisition of the Shares to be issued upon the exercise of the Options may result
in tax consequences. YOU ARE ADVISED TO CONSULT A TAX ADVISER WITH RESPECT TO THE TAX CONSEQUENCES OF RECEIVING OR EXERCISING
THIS OPTION OR DISPOSING OF THE SHARES.

 

	10.	ExceptionsBy
    signing this Grant Notification Letter you hereby acknowledge, accept and agree as to the following:

  

    	 

    	 

    

 

	 	10.1	The
    Company may in the future issue additional Shares and grant additional Options to various entities and individuals, as the
    Company in its sole discretion shall determine.
	 	 	 
	 	10.2	The
                                         Company shall not be obligated to issue any Shares upon the exercise of an Option if
                                         such issuance, in the opinion of the Company, might constitute a violation by the Company
                                         of any provision of law.

	 	 	 
	 	10.3	The
    transfer of Options and the transfer of Shares to be issued to you upon exercise of the Options shall be subject to the limitations
    set forth in the Scheme, Israeli Annex and in the Company's Articles of Association and any shareholders' agreement to which
    the holders of ordinary shares of the Company are bound.
	 	 	 
	 	10.4	You
    shall not dispose any of your Shares in transactions which violate, in the opinion of the Company, any applicable laws, rules
    and regulations.
	 	 	 
	 	10.6	Notwithstanding
anything mentioned above and in addition, you are aware that you will have no rights or privileges of a shareholder with respect
to any Shares purchasable upon the exercise of an Option, nor shall they be deemed to be a class of shareholders or creditors
of the Company for the purpose of all applicable law, until you are registered as a holder of such Shares in the Company's register
of shareholders upon exercise of your Options, all in accordance with the provisions of the Scheme.

 

	11.	Miscellaneous
    The following shall apply with respect to this Grant Notification Letter and shall be bound by you:

 

	 	11.1	No
    Obligation to Exercise Options. The grant and acceptance of the Options granted to you hereunder, imposes no obligation
    on you to exercise it.
	 	 	 
	 	11.2	Confidentiality.
    You shall regard the information in this Grant Notification Letter and its exhibits attached hereto, as confidential
    information and you shall not reveal its contents to anyone except when required by law or for the purpose of gaining legal
    or tax advice.
	 	 	 
	 	11.3	Continuation
    of Employment or Service. Neither the Scheme, the Israeli Annex nor this Grant Notification Letter shall impose any obligation
    on the Company or any of its Affiliate to continue your employment or service and nothing in the Scheme and/or in the Israeli
    Annex and/or in this Grant Notification Letter shall confer upon you any right to continue in the employ or service of the
    Company and/or an Affiliate or restrict the right of the Company or an Affiliate to terminate such employment or service at
    any time.
	 	 	 
	 	11.4	Entire
    Agreement. Subject to the provisions of the Scheme and/or the Israeli Annex to which this Grant Notification Letter
    is subject, this Grant Notification Letter, together with the exhibits hereto, constitute the entire agreement between you
    and the Company with respect to Options granted to you hereunder, and supersedes all prior agreements, understandings and
    arrangements, oral or written, between you and the Company with respect to the subject matter hereof.

 

    	 

    	 

    

  

	 	11.5	Failure
    to Enforce - Not a Waiver. The failure of any party to enforce at any time any provisions of this Grant Notification Letter
    and/or the Scheme and/or the Israeli Annex shall in no way be construed to be a waiver of such provision or of any other provision
    hereof.
	 	 	 
	 	11.6	Provisions
    of the Scheme.The Options provided for herein are granted pursuant to the Scheme and the Israeli Annex, and said Options
    and this Grant Notification Letter are in all respects governed by the Scheme and the Israeli Annex, and subject to all of
    the terms and provisions of the Scheme and Israeli Annex.
	 	 	 
	 	 	Any interpretation
    of this Grant Notification Letter will be made in accordance with the Scheme and the Israeli Annex, however, in the event
    there is any contradiction between the provisions of this Grant Notification Letter and the Scheme and/or the Israeli Annex,
    the provisions of this Grant Notification Letter will prevail.
	 	 	 
	 	 	By signing
    this Grant Notification Letter, you hereby represent and warrant that you have accepted the Grant Notification Letter, and
    have read the Scheme and understand its content and implications including without derogating the restrictions imposed on
    you under Section 102.
	 	 	 
	 	11.7	Binding
    Effect.The Scheme, the Israeli Annex and this Grant Notification Letter shall be binding upon the heirs, executors,
    administrators and successors of the parties hereof.
	 	 	 
	 	11.8	Notices.All
    notices or other communications given or made hereunder shall be in writing and shall be delivered or mailed by registered
    mail or delivered by email or facsimile with written confirmation of receipt to you and/or to the Company at the addresses
    shown on the letterhead above, or at such other place as the Company may designate by written notice to you. You are responsible
    for notifying the Company in writing of any change in you address, and the Company shall be deemed to have complied with any
    obligation to provide you with notice by sending such notice to the address indicated below.

 

	Company's Signature:	 
	 	 
	By:                                                                          	 
	Can-Fite Biopharma Ltd.	 

  

    	 

    	 

    

 

I,
the undersigned, hereby acknowledge receipt of a copy of the Scheme and the Israeli Annex and accept the Options subject to all
of the terms and provisions thereof. I have reviewed the Scheme, the Israeli Annex and this Grant Notification Letter in its entirety,
have had an opportunity to obtain the advice of counsel prior to executing this Grant Notification Letter, and fully understand
all provisions of this Grant Notification Letter. I agree to notify the Company upon any change in the residence address indicated
above.

 

 

[Grantee's
full name & Signature]

 

	Exhibit
    A:	Can-Fite Biopharma Ltd. 2013 Global Incentive Option Scheme &
    Israeli Annex
	 	 
	Exhibit B:	Terms of the Option's
    grant 
	 	 
	Exhibit
    C:	Trust Agreement

 

    	 

    	 

    

 

EXHIBIT
B

TERMS
OF THE OPTION

 

	Grantee's
    name:	 	 
	Date
    of Grant:	 	 
	Designation:	 	 
	 	●	☐
    Approved 102 Option:
	 	 	Capital
    Gain Option (CGO) ☐;or
	 	 	Ordinary
    Income Option (MO) ☐
	 	●	☐
    Unapproved 102 Option
	 	●	☐
    3(i) Option
	 	 	 
	1.
    Number of Options granted:	 	 
	2.
    Purchase Price:	 	 
	3.
    Vesting Dates:	 	 
	 	 	 
	Number
    of Options	 	Vesting
    Date
	 	 	 
	4.
    Expiration Date:	 	 

 

	 	 	 	 
	 	 	 	 
	Grantee's
    name	 	Company

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]